How Much Does Mounjaro Cost in South Carolina in 2026?

Retail and Cash-Pay Pricing Across South Carolina

The manufacturer list price set by Eli Lilly for Mounjaro is $1,023 per month, and South Carolina retail pharmacies track closely to that figure for uninsured patients paying out of pocket. This price applies to a carton of four single-dose pens at any strength from 2.5 mg through 15 mg.

Prices at individual pharmacies across the state vary by only small margins. CVS, Walgreens, and Walmart locations in Charleston, Columbia, and Greenville all cluster near the $1,023 mark without a discount coupon or insurance applied. Independent pharmacies occasionally price 3% to 5% lower, but the difference rarely exceeds $50 per month.

Tirzepatide is a dual GIP/GLP-1 receptor agonist that Eli Lilly markets under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The SURPASS-2 trial (N=1,879) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.58 percentage points versus 1.86 points for semaglutide 1 mg at 40 weeks. That same trial reported mean body weight reductions of 12.4 kg with the 15 mg dose. These dual metabolic effects explain why demand for the drug continues to rise across South Carolina, even as the price remains above $1,000 monthly.

For patients with no insurance pathway, the annual cost of branded Mounjaro exceeds $12,000. That figure makes understanding every available discount channel a financial priority.

South Carolina Medicaid: No Coverage for Weight Loss

South Carolina's Medicaid program does not cover Mounjaro or Zepbound for weight management. Coverage remains restricted to tirzepatide's type 2 diabetes indication under Mounjaro's FDA-approved labeling, and even then, prior authorization requirements apply.

The state's preferred drug list requires documented failure of metformin and at least one sulfonylurea before Medicaid will consider covering a GLP-1 receptor agonist for glycemic control. Patients who meet these step-therapy criteria may gain access to Mounjaro for diabetes, but the approval process typically takes 7 to 14 business days after the prescriber submits documentation.

For the roughly 1.2 million South Carolinians enrolled in Medicaid, this gap means that weight management with tirzepatide requires either commercial insurance, employer coverage, or out-of-pocket payment. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends GLP-1 receptor agonists as first-line pharmacotherapy for patients with a BMI of 30 or greater, yet payer coverage in South Carolina has not aligned with that recommendation for Medicaid enrollees.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, stated in the guideline commentary: "The evidence base for tirzepatide and semaglutide in obesity treatment is now strong enough to support first-line use, and coverage policies need to reflect that clinical reality."

Commercial Insurance Coverage in South Carolina

Commercial insurers in South Carolina handle Mounjaro coverage inconsistently. BlueCross BlueShield of South Carolina, the state's largest private insurer, covers Mounjaro for type 2 diabetes with prior authorization but does not include it on formulary for obesity treatment on most plan tiers.

Patients with employer-sponsored plans from national carriers like UnitedHealthcare, Aetna, or Cigna may have broader access, depending on the specific benefit design their employer selected. The determining factor is whether the plan's pharmacy benefit includes anti-obesity medications. Roughly 40% of large employer plans now include some GLP-1 coverage for weight management, according to the 2024 Kaiser Family Foundation Employer Health Benefits Survey.

Copays for commercially insured patients with formulary coverage typically range from $25 to $150 per month, depending on the plan tier. Patients placed on a non-preferred or specialty tier may face coinsurance of 20% to 40%, translating to $200 to $400 monthly.

Three steps can clarify your coverage quickly. First, call the member services number on the back of your insurance card and ask whether tirzepatide (not just "Mounjaro") is on formulary. Second, ask which tier it occupies and whether prior authorization is required. Third, request the specific step-therapy requirements in writing so your prescriber can submit documentation efficiently.

The Eli Lilly Savings Card: How It Works in SC

Eli Lilly offers a manufacturer savings card that reduces out-of-pocket costs for commercially insured patients to as low as $25 per monthly fill. The card is available through Lilly's patient support portal and activates at the pharmacy counter.

Eligibility requirements are straightforward. Patients must carry commercial insurance (not Medicare, Medicaid, or TRICARE), have a valid prescription for Mounjaro, and reside in a state where savings-card programs are permitted. South Carolina allows these programs without restriction.

The savings card covers the difference between the patient's copay or coinsurance and the $25 floor, up to a maximum benefit per fill that Lilly adjusts periodically. In practice, a patient with a $150 copay would pay $25, and Lilly would cover the remaining $125.

Patients without any insurance do not qualify for the standard savings card. Lilly runs a separate patient assistance program called Lilly Cares for uninsured patients who meet income thresholds. Applicants with household incomes at or below 400% of the federal poverty level ($62,400 for a single individual in 2026) may receive Mounjaro at no cost through this program.

The FDA's Orange Book listing for tirzepatide confirms active patent protection through the late 2030s, meaning generic branded alternatives are not expected to enter the market in the near term. The savings card remains the most reliable cost-reduction tool for commercially insured South Carolina patients.

Compounded Tirzepatide in South Carolina: Legality and Pricing

Compounded tirzepatide is available in South Carolina through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines established by the FDA's Drug Quality and Security Act.

The price point is significantly lower. Compounded tirzepatide typically costs approximately $249 per month at South Carolina 503A pharmacies, representing a 76% reduction from the branded list price.

However, several distinctions matter. Compounded tirzepatide is not FDA-approved. It is prepared from bulk tirzepatide base or salt by a compounding pharmacy, and neither the potency nor the injection device matches the branded product exactly. Patients use standard syringes rather than the Mounjaro autoinjector pen. The compounded formulation also requires refrigeration handling that varies by pharmacy.

The FDA has taken shifting regulatory positions on compounded tirzepatide. In late 2024, the FDA removed tirzepatide from its drug shortage list, which prompted enforcement discussions about whether 503A pharmacies could continue compounding it. As of May 2026, 503A compounding of tirzepatide continues in South Carolina under individual patient prescriptions. Patients should verify with their specific pharmacy that compounding authorization remains active, as enforcement actions can change quickly.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement cautions: "Patients using compounded GLP-1 receptor agonists should be informed that these preparations lack the quality assurance standards of FDA-approved products, including bioequivalence testing and standardized dosing devices."

Dose accuracy is one concern. A study published in the Journal of the Endocrine Society found that 10% to 15% of tested compounded semaglutide samples fell outside the labeled potency range. Similar data for compounded tirzepatide is limited but expected to follow comparable patterns.

Telehealth Access for Mounjaro in South Carolina

South Carolina permits telehealth prescribing of Mounjaro and compounded tirzepatide. The state's telehealth parity laws, updated in 2023, allow prescribers to establish a patient-provider relationship via synchronous video visit and issue prescriptions for scheduled and non-scheduled medications, including injectable GLP-1 receptor agonists.

Several national telehealth platforms operate in South Carolina and offer tirzepatide consultations. These platforms typically charge a monthly membership fee of $50 to $150 in addition to medication costs. Some bundle the consultation fee with compounded tirzepatide at all-in prices ranging from $299 to $449 per month.

Before choosing a telehealth provider, verify three things: the prescriber holds an active South Carolina medical license, the pharmacy is a licensed 503A or 503B facility, and the platform provides ongoing clinical monitoring including weight checks and metabolic lab work. The CDC's guidelines on obesity screening recommend checking fasting glucose, HbA1c, and a lipid panel at baseline and every 3 to 6 months during GLP-1 therapy.

Patients with type 2 diabetes should approach telehealth-only platforms cautiously. Diabetes management requires coordination with existing medications, insulin dose adjustments, and hypoglycemia monitoring that may exceed the scope of some telehealth-only models.

Comparing All Cost Pathways Side by Side

The range of monthly costs for tirzepatide in South Carolina spans from $0 to over $1,023, depending on the access route. Here is how each pathway compares.

Branded Mounjaro at retail without insurance costs $1,023 per month. With commercial insurance and the Lilly savings card applied, the cost drops to $25 to $150 monthly. Lilly Cares patient assistance covers the full cost for qualifying uninsured patients.

Compounded tirzepatide through a 503A pharmacy runs approximately $249 per month without insurance. Telehealth platforms bundling consultations and compounded medication charge $299 to $449 monthly.

For patients with type 2 diabetes, the SURPASS program of clinical trials established tirzepatide's efficacy across five key studies. SURPASS-2 compared tirzepatide head-to-head against semaglutide 1 mg, and tirzepatide 15 mg achieved a statistically superior HbA1c reduction (P<0.001 for all three tirzepatide doses versus semaglutide). Weight loss in that trial reached 12.4 kg with the 15 mg dose versus 6.2 kg with semaglutide 1 mg. These outcomes support tirzepatide's value for patients weighing cost against clinical benefit.

The American Diabetes Association's Standards of Care 2024 list GLP-1 and dual GIP/GLP-1 receptor agonists as preferred second-line agents after metformin for patients with type 2 diabetes and overweight or obesity, reinforcing the clinical rationale for pursuing coverage.

How to Appeal a South Carolina Insurance Denial

Insurance denials for Mounjaro in South Carolina are common, but the appeals process offers a structured pathway to overturn them. South Carolina insurance law requires carriers to provide a written explanation of denial and instructions for appeal within 30 days.

The first-level appeal should include a letter of medical necessity from the prescribing provider, lab results documenting BMI, HbA1c, or other metabolic markers, documentation of failed prior therapies (if step therapy was cited as the denial reason), and the relevant clinical guideline supporting tirzepatide use.

If the first appeal fails, patients can request an external review through the South Carolina Department of Insurance. External reviews are conducted by independent physicians and are binding on the insurer. The success rate for external reviews of specialty medication denials in South Carolina has historically exceeded 40% when supported by guideline-concordant documentation.

A peer-to-peer review between the prescriber and the insurance company's medical director represents another avenue. During this call, the prescriber can present the individualized clinical rationale directly. Many denials that survive written appeal are overturned during peer-to-peer discussions.

Dose Titration and Its Impact on Monthly Spending

Mounjaro's prescribing information specifies a dose titration schedule that starts at 2.5 mg weekly for four weeks, then increases to 5 mg weekly. From there, the prescriber may increase in 2.5 mg increments every four weeks, up to a maximum of 15 mg weekly. The titration period typically spans 20 to 28 weeks before reaching a maintenance dose.

All dose strengths carry the same list price of $1,023 per month for the branded product. This means monthly spending does not change as the dose increases. However, compounded tirzepatide pharmacies sometimes price by milligram, so a patient on 5 mg may pay less than one on 15 mg. Patients using compounded formulations should confirm per-dose pricing before initiating treatment, as the monthly cost difference between 5 mg and 15 mg can exceed $100 at some compounding pharmacies.

The most common side effects during titration are gastrointestinal: nausea (reported in 12% to 18% of patients across the SURPASS trials), diarrhea (12% to 17%), and decreased appetite. These effects typically diminish after 4 to 8 weeks at each dose level, and the gradual titration schedule is designed specifically to improve tolerability.